20 percent more patients were treated with proton therapy in 2019
An individual eye shield is made for each patient to protect the surrounding tissue from the proton beam. © HZB
Number of patients who received the proton therapy offered jointly by Charité and HZB. © HZB/J. Politt
For more than 20 years, Charité - Universitätsmedizin Berlin and the Helmholtz-Zentrum Berlin (HZB) have jointly offered the irradiation of eye tumors with protons. In 2019, more patients were treated in Berlin-Wannsee than ever before. 276 patients - 20 percent more than in the previous year - underwent proton therapy. The treatment is specialized in choroidal melanomas of the eye. The proton accelerator at HZB is the only treatment facility for this disease in Germany.
500 to 600 people in Germany are affected by a malignant choroidal melanoma every year. In 97 percent of cases, the tumour can be completely destroyed by irradiation with protons. In most cases, not only the eye but also the vision can be maintained to a satisfactory degree. "The energy of the proton beam can be adjusted in such a way that practically only the tumor receives the radiation. Since the protons have a straight trajectory, the lateral scattering is much less than with X-rays," explains Dr. Jens Heufelder, the senior medical physicist at Charité - Universitätsmedizin Berlin. The protons effectively destroy the tumor, while the surrounding healthy tissue is largely spared.
To cope with the increase in patients in 2019, treatment operations at the proton accelerator have been extended to 12 hours. Approximately 45 percent of the patients came from the Berlin-Brandenburg region, the other patients came from other German states and other European countries (approximately 8 percent). The youngest patient who received proton therapy at HZB in 2019 was 8 years old, the oldest patient 96 years old. The average age was 61 years.
Since 1998, more than 3,700 patients have been treated with protons from the HZB accelerator. "The success of proton therapy is based on the collaboration between ophthalmologists, medical physicists and accelerator experts. As a result, the therapy has been continuously improved for the benefit of patients over the past few years", explains Prof. Dr. Andrea Denker, head of proton therapy at HZB.
- Nanosilver as an electrocatalyst for CO₂ reductionVia electrolysis, CO2 can be reduced to CO, a raw material for further chemical products such as fuels. Within the GreenQuest Project, an internation team led by HZB chemist Prashanth Menezes has now systematically investigated catalyst layers made of silver nanoparticles, varying both the size of the particles and their density. The best yield was achieved with nanoparticles with diameters of around 10 nm, which were loosely distributed. Furthermore, they demonstrated how the economic efficiency of the electrochemical cell can be enhanced by integrating an additional chemical reaction at the anode, enabling the simultaneous production of a valuable formic acid, hydrogen, and CO in one device.
- Spin waves inside a nano-oscillator imaged for the first timeFor the first time, researchers have directly imaged the magnetisation dynamics inside a spin Hall nano-oscillator — a nanoscale device that converts direct current into tunable microwave signals and is a promising building block for energy-efficient wireless communication and brain-inspired computing. A Swedish–German team led by the University of Gothenburg and Helmholtz-Zentrum Berlin (HZB) achieved this using time-resolved scanning transmission X-ray microscopy at the MAXYMUS instrument at BESSY II. The results, now published in Advanced Materials, reveal spin-wave features that had escaped previous, indirect measurement techniques.
- Joint power instead of duplicate structures:Berlin’s research community is further advancing its research excellence by establishing a high-performance, cross-institutional infrastructure for data and AI. With a joint agreement signed on 18 September 2026, the Berlin University Alliance (BUA), the Helmholtz-Zentrum Berlin (HZB) and the Zuse Institute Berlin (ZIB) are paving the way for a joint data science and AI centre in Berlin-Dahlem and Adlershof.